Pharmaceutics 2020
About Conference
ABOUT CONFERENCE
EuroSciCon invites participants from all over the world to attend ''19th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems” during November 23-24 ,2020 at Rome, Italy which includes prompt keynote presentations, Oral talks (Speaker Forum and Young Research Forum), Poster presentations, Symposium, Workshops and Exhibitions.
Pharmaceutics 2020 spreads an extensive range of critically important sessions from basic research to recent innovations. The theme: “Navigating the Future of Pharmaceutics & Novel Drug Delivery Systems” is designed for professionals at all levels and career phases of the Pharma industry, who want to improve their understanding of what will drive and shape the future of the market.
What’s New?
Pharmaceutics 2020 offers a best stage with its proficient legitimate program to the social event of individuals which consolidates instinctive board discoursed, keynote addresses, all-hands gatherings and notice sessions on the topics Clinical Trails, Drug Discovery, Nanotechnology, current issues in Bioequivalence, Pharmaceutical Innovation in the 21st Century, Nanomedicine, Drug transport, Gene Therapy, Therapeutic Biological Products, Pharmaceutical Packaging, BABE, Biosimilars, Drug Delivery Technologies, Drug delivery advances and challenges, Pharmacovigilance, Tissue Engineering, Regenerative Medicine, Pharmaceutical Chemistry, Pharmaceutical Analysis, new coherent approaches to managing overall managerial measures, Pharmacotherapy, Generic Drugs, Biopharmaceutical Companies and Market Analysis, The get-together invites delegates from over the globe giving a predominant stage, interconnecting the latest research, creative enhancements in the field and furthermore helpful viewpoints. This conference also provides a podium to exhibit the brand-new equipment relate to Pharma Industry for the industries and companies in which they can be benefited in the global market moreover they can upgrade their product value.
Rome Pharma Market
Italy is one of the leading pharmaceutical markets worldwide . The Italian pharmaceutical industry grew considerably over recent years in terms of production, value added, investments, and trade. CDMO (Contract Development Manufacturing Organization), is the main structure of the Italian pharmaceutical industry, with a production value amounting to 1.9 billion euros. Regarding innovation, Italy accounts for 18 percent of the total number of clinical trials authorized in the European Union.
In 2019, the total turnover generated by pharmacies amounted to 25,209 million euros. According to the data provided by New Line Ricerche di Mercato, the revenues coming from the sales of prescription drugs added up to 14,694 million euros, while the segment of commercial products such as non-prescription drugs and OTC made up for the remaining turnover. Regarding the non-prescription segment, self-medication products accounted for 23 percent of the total turnover, whereas dermo-cosmetic products represented 7.3 percent of it.
Target Audience
Nobel laureates in Health Care and Medicine
Scientists
Pharmaceutical companies
Pharmacovigilance Companies
Clinical Laboratories
Supply Chain companies
PHDs
Manufacturing Companies
Pharmaceutical Industrial Giants
Biotechnology Companies
Research Institutes and members
Regulatory Operations and Affairs Outsourcing experts
Pharmacy Students
Pharmacologists
Business Entrepreneurs
Toxicologist
Pharmacists
Toxicology and Pharmacology Students
Pharmacy Societies and the people Associated
Pathology Professionals
Genetic Professionals
Bio-informatics Professionals
Training Institutes
Nursing Professionals
Why to attend our Conference:
This event will provide an opportunity to build and expand your network with various people and gives chance to make collaboration with other universities and research labs. It also helps you to meet the experts in the relevant field of study. It gives the access to novel instruments in the market. This conference plays a major role in your business development and maximizes the profit.
Opportunities for Conference Attendees
For Researchers &Faculty:
Speaker Presentations
Poster Display
Symposium hosting
Workshop organizing
For Universities, Associations & Societies:
Association Partnering
Collaboration proposals
Academic Partnering
Group Participation
For Students & Research Scholars:
Poster Competition (Winner will get Best Poster Award)
Young Researcher Forum (YRF Award to the best presenter)
Student Attendee
Group registrations
For Business Delegates:
Speaker Presentations
Symposium hosting
Book Launch event
Networking opportunities
Audience participation
For Companies:
Exhibitor and Vendor booths
Sponsorships opportunities
Product launch
Workshop organizing
Scientific Partnering
Marketing and Networking with clients
TRACKS/SESSIONS
Track 1: Nanotechnology in Drug Delivery
Nanotechnology became the driving force behind various evolutionary changes in the scientific field. Nanotechnology based drug delivery enhanced the efficacy of available medicaments and enabled to create entirely new medical products. Nanotechnology has opened the door to new innventions to stimulate the reconstruction of complex tissue structures. Nanoparticles are used to deliver the drug to the specific diseased cell where particles attract to the diseased cell and provide treatment. By this technique, we can minimize the damage of healthy cells in the body.
Nanotechnology-dependent detectors e.g. nanowires, nanotubes, nanoparticles, cantilevers, and nano arrays consume low sample and enhance fast detection of disease. Target based Nano probes (e.g. magnetic nanoparticles, quantum dots, and carbon nanotubes) provide a faster, less invasive and more accurate way for diagnose of diseases. Reporting in vivo efficacy of therapeutics and helping surgeons to locate tumors are other opportunities of nanotechnology.
Some nanotechnology-based drugs that are commercially available are- Abraxane, approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer. Doxil was approved by the FDA for the treatment of ovarian cancer.
The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.
Track 2: Targeted drug delivery: Advances and Approaches
Targeted drug delivery is a kind of drug delivery, a method of delivering medication to a patient in a manner that increases the concentration only in particular area of the body. The goal of a targeted drug delivery system is to prolong, localize and have a safe drug interaction with the diseased tissue. The advantages of the this drug delivery are 1. reduction in the frequency of the dosages taken by the patient 2. have an uniform effect of the drug, 3.reduction of drug side-effects 4. reduce fluctuation in circulating drug levels 5.maintain the optimum plasma and tissue drug levels in the body. A small portion of the medication reaches the affected organ in Chemotherapy and roughly 99% of the administered drug does not reach the tumor site.
The following criteria must be taken into consideration while designing a targeted drug delivery: the drug property,the route of drug delivery, the targeted site, disease and the side effects of drug. There are two kinds- active targeted drug delivery such as antibody medications and passive targeted drug delivery such as the enhanced permeabilityand retention effect.
Track 3: Innovative Drug delivery technologies
Drug delivery is the action of administering a medication into the body for a therapeutic effect through various routes. Drug delivery technology modifies drug release profiles, pharmacokinetic parameters to improve product efficacy as well as patient convenience. Conventional routes cannot deliver compounds such as proteins, antibodies, vaccine and gene based drugs because these routes are susceptible to enzymatic degradation or cannot be absorbed into the systemic circulation efficiently due to large molecular size and charge issues.
Technologies include controlled needle-free devices, sustained, controlled transdermal delivery technology and penetration matrix technology for non-invasive delivery. Many innovative technologies for effective drug delivery have been developed that includes implants, nanotechnology, cell and peptide encapsulation, micro fabrication, chemical modification.
Biotechnology advances are leading to develop medications to target diseases more effectively and precisely.
Nanotechnology delivers drugs to targeted cells by nanoparticles. The overall drug consumption and side-effects are lowered significantly by depositing the active drug in the particular site and preventing administration of booster doses. Nanotechnology based devices are less invasive. They can be safely implanted inside the body as biochemical reaction times are much shorter.
Track 4: Recent Advances in Drug Delivery Systems
The goal of drug delivery systems is to deliver medications to specific target parts of the body through a medium that can control the therapy’s administration. To achieve this goal, researchers are switching to advances in the worlds of micro- and nanotechnology.
The recent advances in the peptide,protein drug delivery systems are PEGylation and Depo-foam technology. Cell-penetrating peptides (CPPs) act as cargo carriers and constitute current medical research. CPPs to transport hydrophilic macromolecules into cells, thus, assist to execute biological functions. CPPs do not destroy the integrity of the cell membranes so they are considered more efficient and provide new avenues for research and applications in life sciences.
Needle-free drug delivery systems are novel ways to introduce various medicines to patients. PowderJect Pharmaceuticals one of the first companies to develop a needle-free technology for injecting powdered drugs into the skin. Needle free devices can take the form of power sprays, edible products, inhalers, and skin patches
Transdermal patches are user-friendly, convenient, painless and offer improved patient compliance.
Nano drug delivery systems such dendrimers, fullerence, nano pores, nanotubes, nano shells, quantum dots, , nanovaccines, revolutionized drug delivery systems. Thus nanomaterial can be used for strategic development of new drug delivery systems and reformulate existing.
Anti-cancer drugs such as loperamide and doxorubicin bound to nanomaterial have been shown to cross the blood-brain barrier.
Track 5: Nanoparticles: Innovations and Trends
Nanoparticles are generally less than 100 nm in dimension and consist of different biodegradable materials such as natural or synthetic polymers, lipids, or metals. Nanoparticles are taken up by cells more efficiently than larger micromolecules. Nanoparticles have high surface area to volume ratio thus allowing many functional groups for attachement. The small size of nanoparticles allows them to accumulate at sites.
Nano particles can (1) enhance the efficacy and minimize adverse reactions associated with drugs; (2) enable new classes innovations; and (3) encourage the re-investigation of pharmaceutically suboptimal but biologically active new molecules that were previously considered undevelopable.
Nanoparticles are used in drug delivery to improve the uptake of poorly soluble drugs.
As per BCC Research the global market for nanoparticles in the life science forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate (CAGR) of 22%.
Track 6: Drug Delivery: Facing Challenges
Innovative, non-invasive delivery includes improvement of patient acceptability and compliance, improvement in public safety, decrease of administration costs and a reduction of adverse effects. Enzymedegradation, acid degradation, hydrolysis and low permeability of intestinal epithelium in the GI tract surfaces make oral administration a non-viable delivery method. Proteins are administered parenterally as oral administration cause low bioavailability in the GI tract. It has become a challenge to achieve consistent and adequate bioavailability levels for oral administration.
Economic and financial barriers also stand in the way of implementing nano medicine. The limited availability of reimbursement by public and private health insurers for expensive new diagnostic tests has emerged as a major impediment to the deployment of personalized medicine. Nanoproducts encounter even greater hurdles because of their costs and complexity, cytotoxicity of nanoparticles are main concern of future research.
Advances in medical science, research and development (R&D) are changing the dynamics of the life science industry which includes pharmaceuticals and healthcare. The development of new drugs enhances the development of different drug delivery systems, which is further driven by innovation in technology, R&D and scientific advancements. Advances in understanding human diseases and medical treatments are opening new opportunities in the pharma industry. A better technology for drug administration or delivery is in demand now.
Track 7: Drug delivery through BBB
One of the biggest challenges in the drug discovery and development for CNS disordersis to achieve significant blood–brain barrier (BBB) penetration.
Many drugs do not have high lipid solubility, low molecular size and positive charge to traverse BBB. The issues associated with the blood–brain barrier are 1. The drug produced allows only a small portion to pass through the barrier 2. Binding to other proteins in the body makes the drug ineffective or pass through the barrier with that adhered protein. 3. The presence of enzymes in the brain that could render the drug inactive. All of these problems must be addressed to deliver effective drugs to the brain.
Developed strategies enhance the capacity of drug to cross the BBB by modifying the drug or by coupling it to a vector for receptor-mediated or adsorption-mediated transcytosis.
Compounds using BBB technology in the clinical development would reach approximately eight by 2019. The global market for BBB technologies was valued at $38.7 million in 2014. The market is expected to grow to $471.5 million by 2019, and register a tremendous 64.9% CAGR from 2014 through 2019.
Track 8: Novel Drug Delivery Systems
It is defined as the method by which a drug is delivered can have a significant effect on its efficacy i.e. the drug become more efficient in order to minimize drug degradation, adverse effects and to increase the bioavailability to produce betterresult. NDDS covers various aspects like pharmacokinetics & pharmacodynamics, non-specific toxicity, immunogenicity, bio recognition, and drug’s efficacy based on preferable approaches that include polymer science, pharmaceutical technology, dispensing pharmacy, packaging technology, bio conjugate chemistry, and molecular biology.
Track 9: Drug delivery vehicles
A drug carrier enhances the selectivity, effectiveness and safety of drug administration. Drug carriers are mainly used to control the release of a drug into systemic circulation. This can be accomplished either by slow release of the drug over a long period of time (typically diffusion) or by triggering the release at the target by stimulus, which include pH changes, application of heat and activation by light. Drug carriers improve the bioavailability of poorly water soluble drugs or membrane permeable drugs.
An ideal drug delivery vehicle must be non-toxic, non-immunogenic, biocompatible and biodegradable Different methods of drug attachment to the carriers include adsorption, integration, encapsulation, and covalent bonding.
Track 10: Protein, Peptide and Gene Drug Delivery
Peptides and proteins have more potential as drug delivery systems. Compared with the small size drugs, peptides and proteins can be highly selective as they have multiple contact points with their target. Increased selectivity results in decreased side effects and toxicity. Peptides can be designed to target a broad range of molecules and provide opportunities in oncology, infectious disease and endocrinology fields. The market for peptide and protein drugs is estimated to be greater than US$40 billion/year, or 10% of the pharmaceutical market .At present there are over 100 approved peptide-based drugs in the market. The pharmaceutical scientists have approaches to develop the protein and peptide delivery formulations by noninvasive routes.
Gene therapy is defined as incorporation of genetic material i.e, DNA or RNA, in the cellular gene regulation system, either to correct the expression of a malfunctioning gene or to modulate the cellular functions. Nanotechnology advances gave rise to the development of nanoparticle-DNA delivery systems. Gene delivery is an important part of genome evolution. Gene delivery utilizes non-immunogenic vectors capable of cell specificity that can deliver an adequate amount of transgene expression to cause the desired effect. Gene therapy advanceshave enabled a variety of new methods and gene targets to be identified for possible applications. Gene delivery has been utilized to generate a hybrid biosynthetic vector to deliver a possible vaccine.
Track 11: Pharmacokinetic and Pharmacodynamic Studies
Pharmacokinetics describes how the medicament gets influenced after administration, followed by absorption, distribution, metabolism mechanisms and excretion of the drug substance. Pharmacokinetic knowledge assists prescribers to adjust dosage accurately and precisely. Clinical kinetics is defined as the applications of pharmacokinetic principles in the safe and adequate management of individual patient. Toxic pharmacokinetics is defined as the applications of pharmacokinetic principles to the designation, behaviour and interpretation of drug safety evaluation studies.
Pharmacodynamics describes biochemical, physiological, and molecular effects of drugs on the body and involves receptor binding (including receptor sensitivity), post receptor effects, and chemical reactions. The pharmacological response depends on the drug binding to its target. The effect of drug presence at the site of action is measured by drug-receptor binding.
Track 12: Drug Discovery, NCEs and Drug Development
Drug discovery is the process in which potential new medicines are recognized and comprises an effective range of scientific disciplines, including biology, chemistry and pharmacology. The integration of pharmacodynamics and pharmacokinetic parameters in non-clinical pharmacology studies plays a key role in drug discovery for efficacy and safety assessment, in particular for translation from the non-clinical to clinical field and process of drug discovery include the identification , synthesis, characterization, screening, and assays for therapeutic efficiency and modern drug discovery involves the identification of screening areas, medicinal chemistry and optimization of those areas to increase the affinity, selectivity, efficacy/potency, metabolic stability, and oral bioavailability.
FDA provides scientific and regulatory advice to bring new therapies to market. In 2018, FDA has approved 43 new drugs which are currently in the market. Every year, CDER approves series of new drugs and biological products. The availability of new drugs represents new treatment options for patients and advances in health care. Some of these are often innovative new products that never before have been used in clinical practice. A new chemical entity (NCE) is a drug that contains no active molecule that has been approved by the FDA in any other application submitted under the Federal Food, Drug, and Cosmetic Act
Track 13: Pharmacovigilance, Risk Management and Drug safety
Pharmacovigilance and Risk Management comprises set of pharmacovigilance activities designed to identify, characterise, prevent or minimize risks related to medicinal productswhich includes the assessment of the effectiveness of their clinical interventions and combination therapies. Drug industry need to promote companies in pharmacovigilance practice to use information technology and to review softwares used in pharmacovigilance and clinical trials. Monitoring unlicensed, off labels and orphan drugs is major task in risk management. Many experts from different pharmacovigilance CRO’s, pharmacovigilance service providers and industrial delegates are participating in this conference to share their knowledge and discuss about the new updates. Pharmacovigilance legislation focus on the rules and laws to follow in Pharmacovigilance practice. The Role of Pharma industries in the improvement of pharmacovigilance systems plays a crucial role to maintain the safety data, Detection and Evaluation of drug safety signals through medical devices reporting. Pharmacovigilance scope also deals as Ecopharmacovigilance(EPV), pharmacoenvironmentology and pharmacovigilance in herbal medicines
Prescription Safety is the pharmacological science ensuring security and related to the aggregation, area, assessment, watching, and repugnance of hostile side effects with pharmacological movement of pharmaceutical things. As per US FDA a drug is seen as protected by its look, collecting technique and delayed consequences of animal testing and clinical tests. In this conference, we look at Drug security and its applications in various fields, for instance, Software, Training.
Track 14: Smart Materials for Drug Delivery
Materials are called “smart” when these materials have the ability to respond to stimuli and have high potential in delivery systems. The drug delivery to specific parts in the human body using smart materials has been approaching the forefront place in research for the past few decades. Materials for delivering drugs that do not interact non-specifically within the body must design drug carriers
Polymers have played an important role in the advancement of drug delivery technology by providing controlled release of agents in constant doses over longer duration and release of both hydrophobic and hydrophilic drugs. The greatest advantage of polymers is their ability to chemical modification, resulting in defined chemical composition, surface functionality and the potential for three-dimensional structures. Several polymers widely used are synthetic polymers and natural polymers.
Nano materials are used in controlled drug delivery. Drug-delivery systems can be designed with controlled composition, shape, size and morphology. Nanoparticles surface properties can be manipulated to increase solubility, immunocompatibility and cellular uptake.
Natural gums are widely used in the drug delivery system because of their wide availability, inexpensiveness.
Track 15: Herbal Novel Drug Delivery
Novel drug delivery systems address the drawbacks of the traditional drug delivery systems. We have a knowledge of Ayurveda. So it is important to integrate novel drug delivery system and Indian Ayurvedic medicines to combat serious diseases.
Reasons for using herbal medicines are 1. Growing concern over the reliance and safety of drugs 2.Failure of modern medicine to treat most common health conditions 3. Natural medicines are producing better results without adverse effects.
Novel herbal formulations like polymeric herbal Nano-carriers, phytosomes, herbosomes, pro-niosomes, Nano emulsions, microsphere, transferosomes, implants and ethosomes has been reported using bioactive plant extracts. Advantages include Solubility, bioavailability enhancements, reduced toxicity, improved pharmacological activity, sustained delivery, and protection from physical and chemical degradation. Many formulations are produced from herbal drugs such as curcumin, quercetin, silybin, bilobalide, marsupsin, andrographolide.
According to WHO due to poverty and lack of access to modern medicine as well as self-belief, about 65-80% of the world's population living in developing and developed countries depends on plants for primary health care facilities.
Track 16: Preformulation and Formulation Aspects
Preformulation studies are important for various phases of clinical trials. Preformulation studies act as the first step as well as the scientific foundation for formulation design and development. These studies provide guidance in selection of drug, excipients, to determine chemical composition, physical pattern and assist in adjustment of pharmacokinetic profiles. Improving public safety measures and intensifying product quality, safety, accuracy are the other characteristics.
The main purpose of pre-formulation studies is to improve compatibility with the other ingredients and develop stable, potent and safe dosage form. Physico-chemical parameters, drug solubility studies, partition coefficient, dissolution kinetics, polymorphism and stability profiles play a significant role in preformulation studies. These studies furnish the information regarding the degradation process, toxic effects and adverse conditions. So Preformulation is an interdisciplinary basis in drug development.
Formulation is defined as the process in which different chemical substances including the active ingredient are compounded to produce a final dosage form. Developed formulations should be stable, safe and acceptable to the patient.
Track 17: Novel Vaccine Delivery Systems
Vaccine is a material that induces an immunologically mediated resistance to a disease. Vaccines are generally composed of killed or attenuated organisms or subunits of organisms or DNA encoding antigenic proteins of pathogens. Vaccines though exceptionally selective and specific in reacting with antibodies often fail to show reactions in circumstances such as shifts in epitopic identification center of antibody and are poorly immunogenic. These vaccines require boosting with agents called adjuvants in order to induce an effective immunity. Adjuvants potentiate the immunostimulatory property of the antigen and are non-immunogenic, nontoxic, and biodegradable in nature.
Conventional immunization regimen involves prime doses and booster doses. Immunization failed as patients neglect the booster doses. These reasons led the development of new generation of prophylactic and therapeutic vaccines to promote effective immunization. Vaccines allow for the incorporation of doses of antigens so that booster doses are no longer needed as antigens are released slowly in a controlled manner. Attempts are being made to deliver vaccines through carriers as they control the spatial and temporal movement of antigens to immune system thus leading to their sustained release and site targeting. Carrier systems such as liposomes, microspheres, nanoparticles, dendrimers, micelles and ISCOMs are being investigated and developed as vaccine delivery systems
Track 18: Novel Drug Delivery: 2D and 3D Printing applications
Activities have been increased regarding the development and research on various printing techniques in formulation of dosage forms. These technologies offer flexibility in manufacturing, pave the way for personalized dosing and dosage forms.
Drug delivery from 3-dimensional (3D) structures is quick growing area of research. 3DP can design solid dosage forms with variable densities and diffusivities, complex internal geometries, multiple drugs and excipients.
3DP uses computer aided technology and programme to transform 3D computer aided designs (CAD) into life-changing products. These develop more effective and patient-friendly pharmaceutical products as well as bio-inspired medical devices. Levetiracetam(SPRITAM®) tablet a pharmaceutical product is developed by using 3DP technology.
3DP offers advantages like (a) high production rates due to its fast operating systems, (b) ability to achieve high drug-loading with desired accuracy mainly for potent drugs that are applied in small amount , (c) reduction of material wastage that can save in production cost and (d) amenability to pharmaceutical active ingredients including poorly water-soluble drugs, proteins as well as drug with narrow therapeutic windows.
3D structures can be printed on a variety of surfaces with characteristic permeability, porosity, hydrophobicity/hydrophilicity and surface energy. Scientists in collaboration with CAD designers have produced new medical devices ranging from pharmaceutical tablets to surgical transplants of the human face and skull, spinal implants, prosthetics, human organs and other biomaterials.
Track 19: Clinical Research and Clinical Trials
Clinical trial is a part of clinical research that follows particular protocol, or plan of action. Clinical trials are mainly performed to obtain data on safety and efficacy of the new developed drug, this data is mandatory for further approval of the drug and to bring it into the market. Clinical trials, especially those taking new medications, regularly begin after effective examines.
Clinical trials are classified into 4 types. The fourth trial occurs after the FDA has cleared a specific medication or treatment and keeps on following the security of the treatment. A clinical review includes inquire of utilizing human volunteers (called members) that add to therapeutic learning. Test potential medicines in human volunteers to see whether they ought to be endorsed for more extensive use in the all-inclusive community
The clinical trials market size was valued at USD 40.0 billion in 2016 and is expected to grow at a CAGR of 5.7% until 2025.
The interventional study design is the most essential method of conducting clinical trials across the globe. As per the statistics provided by the U.S. FDA, over 126,000 trials are currently being conducted by means of this method. Based on this indication, oncology is anticipated to witness the fastest growth.
Track 20: Pharmaceutical Regulatory affairs and Intellectual Property Rights
Regulatory affairs is a new profession which developed from the governments desire to protect public by controlling the safety and efficacy of products in areas including pharmaceuticals , industrial pharmacy, veterinary medicines, medical devices. Regulatory Affairs is involved in the development of new medicines from early stage, by incorporating regulatory principles, by preparing and submitting the relevant regulatory documents to health authorities. Regulatory Affairs is actively involved in every step of development of a new medicine and in the post-marketing activities with authorized medicines. The Regulatory Affairs department is an essential part of the organizational structure of pharmaceutical industry. Internally it assist at the interphase of drug development, manufacturing, marketing and clinical research. Externally it is the key interface between the company and the regulatory authorities.
Track 21: Pharmaceutical Manufacturing and Scale Up Process
The biopharmaceutical sector in US enjoys 17% of all domestic R&D funded by the country and in return gave $2.5 trillion cumulative addition in economic output in 2016. Companies involved in the pharmaceutical manufacturing have grappled in recent years owing to the largest waves of drug patent expirations in history. As a consequence enabling low-price generic drugs to inundate the market. Many pharmaceutical manufacturers have contended with intensifying competition from generic manufacturers and cutting into revenue growth. Until the next five years till 2022, investments in research and development that generate a high return will occur as many pharmaceutical manufacturers strengthen their drug pipeline with orphan drugs.
Recently, engineers have shown inclination to single-use, modern and continuous manufacturing technologies to improve efficiency, safety and minimize scale-up steps and technology transfer problems in the pharmaceutical industry. Lot of these innovations are driven by updates instigated by the FDA. The changes are inevitable; especially in the already aging biopharmaceutical sector of the industry, where original processes are overly complex and are characterized by inefficiency, and occasionally, inherent unpredictability.
Track 22: Pharmaceutical Chemistry
Pharmaceutical chemistry is a branch that includes synthetic organic chemistry, pharmacology and biological specialties, where they involve in the design of drugs, synthesis and development. Pharmaceutical chemistry focuses on small molecules / organic entities encompassing synthetic organic chemistry, aspects of natural product chemistry and computational chemistry in close relation with chemical biology, enzymology and structural biology, together with the goal of discovery and drug development of new different agents. Speaking in practical terms, it involves chemical aspects of identification and, subsequently, a systematic and exhaustive synthetic alteration of new chemical entities to make them appropriate for use. It includes synthetic and computational aspects of the study of drugs and agents existing in the development in relation to their biological activities to understand their structure-activity relationship (SAR). Pharmaceutical chemistry focuses on the aspects of medicines and aims to ensure the adequacy, efficiency of the purposes of the medicines.
Track 23: Pharmaceutical Analysis
Chromatography and Mass Spectrometry are extensively used in the drug development stage of generic products. The ICH Q3B guidelines address the reporting threshold, identification threshold, and threshold for impurities in the product. Chromatography (LC) and Gas Chromatography (GC) are extensively used to analyze stable compounds. Labile compounds require derivatization prior to Liquid Chromatography or Gas Chromatography analysis. For certain analyses, Liquid Chromatography- Ultraviolet Detection (LC-UVD) and Gas Chromatography-Flame Ionization Detection (GC-FID) techniques may be deemed suitable. However, Liquid Chromatography-Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry (GC-MS) are techniques of choice when higher specificity and sensitivity are required. Gas Chromatography-Electron Capture Detection (GC-ECD) techniques are commonly used for halogenated PGIs/GIs to enhance sensitivity and selectivity. Some spectroscopic techniques like Nuclear Magnetic Resonance (NMR), light scattering, and Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) are used in analyzing PGIs/GIs.
Track 24: Biologics and Biosimilars
A biopharmaceutical, otherwise called a biologic therapeutic item or biologic, is any restorative item made in, extricated from, or semi orchestrated from organic sources. Not quite the same as synthetically incorporated pharmaceuticals, they incorporate immunizations, blood segments, allergenic, substantial cells, quality treatments, tissues, recombinant protein and living cells used as a part of cell treatment. Biologics can be made of sugars, proteins, nucleic acids, complex mixtures of these substances, from live cells or tissues. They are confined from normal sources—human, creature, or microorganism. Phrasing encompassing biopharmaceuticals fluctuates amongst gatherings and elements, with various terms alluding to various subsets of therapeutics inside the general biopharmaceutical class. Some offices utilize the terms natural items or remedial organic item to allude particularly to macromolecular items like protein-and nucleic acid–based drugs, recognizing them from items like blood segments or antibodies which are extricated specifically from a natural source Gene-based and cell biologics are at the front line of biomedical research, and might be utilized to treat therapeutic conditions for which no different medications are accessible.
Track 25: Pharmaceutical Packaging and Marketing
Packaging is one of the largest industrial sector in the world that worth several billions. Pharmaceutical packaging are of 3 types, which are: solid packaging, semi-solidspackaging and liquid packaging. The pharmaceutical packaging is a very profitable industry and it is estimated that for 2022 it will reach USD. 8.24 billion. Pharmaceutical packaging represents a meagre percentage of this colossal market. The Global Logistics Market is expected to grow at a CAGR of 7.0% from 2016-2021 and CAGR of 5.6% from 2021-2027. By 2020, pharma cold-chain logistics will be worth $16.7 billion, and non-cold chain at $77.1 billion. The market was estimated at $14.84bn in 2016 and is expected to grow to $28.75bn in 2027.
Track 26: Generic drugs, generic pills and generic medication
A nonspecific medication is characterized as "a medication item that is referred to a brand/reference medication item in measurements of quality, quality, execution attributes, and planned utilization." It is characterized as a term alluding to any medications showcased under its concoction name without any publicity as opposed to the promoted mark name under which the medication is sold out. They are not connected with a specific organization but nonspecific medications are liable to the directions of the nation’s admirations where they are apportioned. Worldwide nonspecific is marked with the name of the maker and the received name of the medication. A nonspecific medication and OTC Drugs must have indistinguishable dynamic fixings.
Generic drugs allow access to health care for all Americans. They are brand-name drugscopies and are the same as those brand name drugs in dosage form, safety, efficacy, strength, administration routes, quality, performance and intended use. Health care professionalscan be assured that FDA approved generic drugs have met the same standards as the innovator drug. All generic drugs approved by FDA should have the same high quality, strength, purity and stability as brand-name drugs. The generic manufacturing, packaging, and testing methods must pass the same quality standards as those of brand name drugs.
Track 27: Tissue Engineering and Regenerative Medicine
Tissue Engineering is characterized as understanding the standards of tissues and its development by practical trade of deficient tissue for clinical utilization. Tissue building deals about the study of combination of cells, designing, materials strategies, physicochemical and biochemical components to replace or enhance natural tissues. Tissue Engineering utilize Scaffoldsto form functional tissues and organs, which can be implanted back into the donor host with the use of engineering techniques and materials process along with some physicochemical factors. It is related to more than one branch which applies engineering knowledge as well as life science concepts towards the development of biological substitutes which can enhance or restore physiological characteristics of organ.
Regenerative Medicine is branch of translational research in tissue designing which manages the way towards supplanting, recovering human cells, tissues or organs to re-establish capacity. Instruments used to understand the results are tissue building, cell treatments, restorative gadgets and manufactured organs.
Track 28: Transdermal and Intradermal Drug Delivery Systems
Transdermal Drug Delivery system is a part of drug delivery system and involves more research. Drugs having long pharmacokinetic half-lives are considered to be unfit for transdermal application. By the increased number of marketing authorization applications along with recent scientific developments for transdermal patches, the need for clear guidance and reserach on specific requirements for this dosage form increased.
The emergence of technological innovations in transdermal patches is expected to provide the market with advances growth opportunities over the coming years. Transdermal Drug Delivery system was valued at $32,516 million in 2016, and is estimated to reach $61,689 million by 2023, growing at a CAGR of 9.5%.
Track 29: Pharmaceutical Technology
Pharmaceutical technology is the scientific knowledge or technology utilized in pharmacy, pharma companies,pharmacology, toxicology and the pharmaceutical industry. It excludes design, techniques, devices and instrumentation in the manufacture, preparation, synthesis, compounding, dispensing, packaging, and accumulating of narcotic and other preparations used in diagnostic, to determine procedures and in the treatment of patients.
Track 30: Pharmacotherapy Effect on Drug Delivery Systems
Pharmacotherapy can be characterized as the treatment, counteractive action of disease by methods for medications of the synthetic or organic root. It positions among essential techniques for therapeutic treatment, together with surgery, physical therapy, radiations, and psychotherapy. Although it is practically difficult to appraise the correct degree of pharmacotherapy effect on human well-being, pharmacotherapy together with enhanced sanitation, eating regimen and better lodging has improved individuals. Phenomenal advancements in genomics and atomic science offer a plenty of new medication targets. The utilization of present day manufactured strategies enhances the blend of medication in shorter circumstances than at any other time.
Track 31: Routes of Drug Administration
The route of administration is the path through which the dosage form (active substance) is administered into the body for treatment of various diseases and disorders. Routes of administration are classified based on 1.the location at which the dosage form is applied 2. Target of action. These include oral, topical and enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).
Taking them correctly and understanding the right way to administer can reduce the risks. The route used to administer a drug depends on three main factors: 1. the part of the body being treated 2.the way the drug works within the body 3.the formula of the drug. These routes enhance the bio availability of drug molecule.
The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. This market analysis is based on route of administration, facility of use.
MARKET ANALYSIS
Pharmaceutical Market: Rome
The global pharmaceutical drug delivery market is projected to reach USD 1,694.7 billion by 2023 from USD 1,244.4 billion in 2018, at a CAGR of 6.4% during the forecast period. Growth in this market is mainly driven by the rising prevalence of chronic diseases, growth in the biologics market, and technological advancements and new product launches.
Based on route of administration, the pharmaceutical drug delivery industry is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The Topical Drug Delivery market is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the wide range of advantages associated with this route of administration, including convenience and ease of use, right dosage to the right place, painless and noninvasive delivery, superior spreadability, and enhanced patient compliance.
Drug discovery services are widely used in forensics, paternity testing, disaster victim identification, and anthropology with DNA analysis/profiling being a key tool in this sector. The global drug discovery services market is expected to reach USD 14.40 Billion by 2022 from USD 8.32 Billion in 2017, at a CAGR of 11.6%. The major factors driving the growth of this market are increasing research and development expenditure, inclination of major pharmaceutical companies towards outsourcing to avoid hurdles, and increasing demand for outsourcing of analytical testing and clinical trial services.
The drug discovery services market is segmented on the basis of process, type, drug type, and therapeutic area. On the basis of process, the global market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification segment is expected to account for the largest share of the market in 2017. The growth in this segment is primarily attributed to emerging advanced technologies for high-throughput screening (HTS).
Based on type, the drug discovery services market is segmented into medicinal chemistry, biology services, and drug metabolism and pharmacokinetics (DMPK). In 2017, the medicinal chemistry segment is expected to account for the largest share of the market. Increasing R&D expenditure, growing number of drug discovery and developmental activities, and increasing inclination of pharmaceutical companies towards outsourcing are among the major factors driving the growth of the medicinal chemistry segment.
On the basis of drug type, the drug discovery services market is segmented into small molecules and biologics. In 2017, the small molecules segment is expected to account for the largest share of the global market. Small molecule drugs are simple, well defined, and easy to characterize. Due to their features, they can easily enter cells, affect other molecules, and cause cancer cells to die. As a result, many targeted therapies are small molecules or small-molecule inhibitors.
By therapeutic area, the drug discovery services market is segmented into oncology, neurology, cardiovascular diseases, respiratory diseases, diabetes, and other therapeutic areas. In 2017, the oncology segment is expected to account for the largest share of the global market. The market is mainly driven by increasing number of cancer patients, which leads to a high demand for cancer therapies.
By region, the drug discovery services market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market is dominated by North America, followed by Europe. However, the Asia Pacific region is expected to witness the highest growth during the forecast period due to less stringent regulations and economical manufacturing costs.
The high cost involved in drug discovery & development and stringent regulations governing drug discovery and animal usage are expected to restrain market growth during the forecast period.
Albany Molecular Research Inc. (AMRI) (US), Charles River Laboratories (US), Evotec (Germany), Domainex (UK), GenScript (US), Covance (US), WuXi AppTec (China), Pharmaceutical Product Development, LLC (PPD) (US), Jubilant Biosys (India), GE Healthcare (US), Merck (Germany), Piramal Enterprises (India), and Advinus Therapeutics (India) are some of the leading players in this market.
LEARN MORE
LEARN MORE
Harvard University | University of Cambridge | University of California, San Francisco | University College London |Formulation Conferences|University of North Carolina | Karolinska Institute |Pharma Conferences 2019 Asia | Yale University | King's College London | University of California, San Diego | Cardiff University | Stanford University |Pharma Conferences 2019 Europe| The Imperial College of Science, Technology and Medicine | Pharmacology Conferences |The University of Manchester | The University of Texas | Utrecht University | Pharma Conferences 2019 USA | The University of Dundee | Clinical Trials Conferences |Columbia University | Monash University | University of Oxford | Pierre and Marie Curie University |Pharmaceutical Conferences 2019| Medical University of Vienna | Drug Discovery Conferences|Rockefeller University | Uppsala University | University of Pennsylvania | University of Zurich |Antibiotics Conferences | University of Tuebingen | The Ohio State University | Pharma Conferences | Radboud University Nijmegen| Ethanopharmacology Conferences|Norwegian University of Science and Technology | Vanderbilt University | McGill University | Pharmaceutical Conferences 2019 USA|University of Hamburg | University of Lausanne | University of Paris Descartes |Pharmacovigilance Conferences| The University of Tokyo | University of California, Berkeley |Pharma Conferences 2019 | Swiss Federal Institute of Technology Zurich | Kyoto University | University of Wisconsin – Madison|Pharmaceutical Conferences 2019 Asia | University of Arizona | Pharmacognosy Conferences |University of South Florida|Pharmaceutical Conferences| University of Utah | China Pharmaceutical University
University of Southern California | CUNY York College | Purdue University | University of Wisconsin-Madison |Drug Discovery Conferences| Albany College of Pharmacy and Health Sciences | University of North Carolina | Clinical Trials Conferences | University of Colorado | Oregon State University |Pharma Conferences 2019 USA | Nova Southeastern University | Massachusetts College of Pharmacy and Health Sciences | University of Florida College of Pharmacy |Pharmaceutical Conferences | University of Michigan College of Pharmacy | Antibiotics Conferences|Campbell University School of Pharmacy | University of Pittsburgh School of Pharmacy|Pharma Conferences 2019 |University of Georgia College of Pharmacy | Temple University School of Pharmacy | Ernest Mario School of Pharmacy |Pharma Conferences 2019 Asia | Skaggs School of Pharmacy | Eugene Applebaum College of Pharmacy and Health Sciences | University of North Carolina|Pharmacology Conferences | University of Minnesota | Ethanopharmacology Conferences|University of California—San Francisco | University of Michigan—Ann Arbor | Pharmacovigilance Conferences |University of Texas—Austin | Ohio State University |Pharma Conferences 2019 Europe | University of Illinois—Chicago |Formulation Conferences | University of Kentucky | Purdue University | University of Florida | University of Maryland—Baltimore | Pharmaceutical Conferences 2019 Asia|University of Pittsburgh | Pharmacognosy Conferences |University of Southern California| University of Washington| University of Wisconsin—Madison | University of Arizona | University of Iowa |Pharma Conferences | University of Tennessee Health Science Center | University of Utah | University of Kansas | Virginia Commonwealth University|Pharmaceutical Conferences 2019 | University at Buffalo | University of Colorado—Denver | Auburn University | University of California—San Diego | University of Oklahoma|Pharmaceutical Conferences 2019 USA | Northeastern University
Kingston University | Ethanopharmacology Conferences |Anglia Ruskin University | Aston University School of Life and Health Sciences | University of Birmingham | Pharmacology Conferences |University of Brighton | Pharmaceutical Conferences |Cardiff University | University of Huddersfield Chemical Sciences | Pharmaceutical Conferences 2019 Asia |University of Huddersfield Pharmacy |Pharmacognosy Conferences| Liverpool John Moores University School of Pharmacy and Biomolecular Sciences |Pharma Conferences 2019 |London Metropolitan University |Drug Discovery Conferences|Loughborough University |Pharmaceutical Conferences 2019| Newcastle University Northern Institute for Cancer Research | Nottingham Trent University School of Science and Technology | University of Nottingham School of Pharmacy | University of Strathclyde |Pharma Conferences 2019 USA| University of Copenhagen | Pharmaceutical Conferences 2019 USA |University of South Wales | University of Bradford | European University Cyprus | University of Groningen|Formulation Conferences | University of Central Lancashire | Pharma Conferences 2019 Asia |University of Debrecen |Clinical trials Conferences|Tu Braunschweig University| Marburg University | Greifswald University | Frankfurt University | Freiburg University|Pharma Conferences| Kiel University | Wurzburg University | Fu Berlin University | Antibiotics Conferences |Lomonosov Moscow State University |Pharma Conferences 2019 Europe| Saint-Petersburg State University | Pharmacovigilance Conferences |Novosibirsk State University
University of Tokyo |Pharmacology Conferences | National University of Singapore| Formulation Conferences |Kyoto University | Pharmacovigilance Conferences |University of Hong Kong | Peking University |Pharma Conferences 2019 Europe | Seoul National University | National Taiwan University | Antibiotics Conferences |Osaka University | Tsinghua University | Pharmaceutical Conferences|Chinese University of Hong Kong| Fudan University |The Hong Kong University of Science and Technology | Pharma Conferences 2019 | Taipei Medical University | Pharmacognosy Conferences |Mahidol University |Drug Discovery Conferences | Korea Advanced Institute of Science and Technology|Pharmaceutical Conferences 2019| Yonsei University | Shanghai Jiao Tong University|Pharma Conferences 2019 USA| Nanyang Technological University | Chulalongkorn University | Tohoku University | Tokyo Medical and Dental University |Ethanopharmacology Conferences | Kyushu University |Pharma Conferences |Nagoya University | Hokkaido University | Sungkyunkwan University | Clinical trials Conferences |University of Science and Technology of China |Pharma Conferences 2019 Asia | Pohang University of Science and Technology | Pharmaceutical Conferences 2019 USA |Korea University | University Malaya |Pharmaceutical Conferences 2019 Asia | Indian Institute of Science
PAST CONFERENCE REPORT
PAST CONFERENCE REPORT
Thanks for participating in Pharmaceutics 2019
Pharmaceutics 2019
The 18th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems was held on October 14-15, 2019 at Warsaw, Poland with the presence of professional researchers, business delegates, scientists involved in the development of high-quality education & research in all aspects. Please check the website: Pharmaceutics 2019 Conference Photographs
Pharmaceutics 2019 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various topics related to the fields of Pharmaceutics and Drug Delivery Systems. The highly exalted conference hosted by EuroSciCon was marked with the attendance of renowned and brilliant researchers, business delegates and talented student communities representing more than 30 countries around the world. The conference has tried grounding every aspect related to Pharma Industry, covering all the possible research areas.
The conference aimed a parallel rail with theme “Exploring the future of Pharma Industry through Pharma research, Nanomedicine and Drug Delivery Systems”. The meeting engrossed a vicinity of cognizant discussions on Targeted Drug Delivery System: Advances and Approaches, Nanotechnology in Drug Delivery, Drug Discovery and Development Obstacles, Drug Delivery through BBB, Innovative Drug Delivery Technologies, Pharmacokinetic and Pharmacodynamic Studies, Smart materials for Drug Delivery, Protein, Peptide and Gene Drug Delivery, Recent Advances in Drug Delivery Systems, Drug Delivery Vehicles, Nanoparticles: Innovations and Trends. The three days event implanted a firm relation of upcoming strategies in the field of Pharma Industry with the scientific community. The conceptual and applicable knowledge shared, will also foster organizational collaborations to nurture scientific accelerations.
We are thankful to all our speakers for encouraging and supporting us to conduct the conference and catapulting the same to pinnacle of success.
We would like to thank our Organizing Committee Members Dr. Vladimir P Torchilin, Northeastern University, USA , Dr. Sergey Suchkov, Sechenov University, Russia for their support throughout the conference without your cooperation which lead us to the grand success of Pharmaceutics 2018 Conference
The Organizing Committee would like to thank the moderator: Dr. Ayse Nur Oktay, Gazi University, Turkey and Olga Mikhailovna Mulina, N D Zelinsky Institute of Organic Chemistry-RAS, Russia for their valuable contribution which resulted in smooth functioning of the conference.
We would also like to thank our Poster judge Dr. Sergey Suchkov, Sechenov University, Russia for the evaluation of Poster Presentations.
The meeting was embarked with an opening ceremony followed by Keynote Sessions and followed by series of lectures delivered by Honorable Guests and members of the Keynote forum. The highlights of the meeting were the eponymous lectures, delivered by:
Vladimir P Torchilin, Northeastern University, USA
Alexander O Terentev, N D Zelinsky Institute of Organic Chemistry-RAS, Russia
Muna Abubaker, University of Salford, UK
Essam Ghanem, Celyad Biopharmaceutical, Belgium
Dushkin Alexandr Valerevich, Institute of Solid State Chemistry SB RAS, Russia
Alyabyeva Zhanna Yurievna, Pirogov Russian National Research Medical University, Russia
Olga V Dementeva, Frumkin Institute of Physical Chemistry and Electrochemistry of RAS, Russia
Ruey-an Doong, National Chiao Tung University, Taiwan
Jayvadan K Patel, Sankalchand Patel University, India
Tamara Zwain, University of Central Lancashire, UK
Yong-Xi Li, Medpace Bioanalytical Laboratories, USA
Sergey Suchkov, Sechenov University, Russia
Dimosthenis Mavrilas, University of Patras, Greece
Ayse Nur Oktay, Gazi University, Turkey
Ilya Yakavets, Belarusian State University, Belarus
Ruth Belostotsky, Shaare Zedek Medical Center, Israel
Suneel I Majagi, Gadag Institute of Medical Sciences, India
Zahid Iqbal, Isra University, Pakistan
Fatemeh Farjadian, Shiraz University of Medical Sciences, Iran
Anika Staack, MEDICE, Germany
Poster competition also held for the young scientists and the best poster presenter has been awarded by the Dr. Sergey Suchkov, Sechenov University, Russia.
Pharmaceutics 2019 had an effective networking session which enables the professionals and scientists to get involved & enlightened them in all perspectives. We also like to thank all the delegate professionals from various countries like India, Nepal who attended the conference shared their industrials experiences in networking sessions.
EuroSciCon is prerogative to thank the Organizing Committee Members, Keynote speakers and Chairs on transcribing the plenary sessions in a diversified and variegate manner to make this conference an enviable artifact.
Pharmaceutics 2019 would not have reached the pinnacle if not with the support of International, multi-professional steering committee and coordination of International Journal of Drug Development and Research, American Journal of Drug Delivery and Therapeutics and Journal of Pharmacy and Pharmaceutical Research.
With the grand success Pharmaceutics 2019, we are glad to announce our next upcoming conference “18th Edition of International Conference and Exhibition on Pharmaceutics and Novel Drug Delivery Systems ” which is going to be held in Rome, Italy during Novemeber 23-24, 2020 on the theme "Navigating the Future of Pharmaceutics & Novel Drug Delivery Systems”
Bookmark your dates…
Hoping to meet you again coming year!!!